These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
    Author: Fragoso YD, Arruda CC, Arruda WO, Brooks JB, Damasceno A, Damasceno CA, Finkelsztejn A, Finkelsztejn J, Gama PD, Giacomo MC, Gomes S, Goncalves MV, Matta AP, de Morais MM, Oliveira EM, Ribeiro Y, Sato HK, Tauil CB.
    Journal: Arq Neuropsiquiatr; 2014 Sep; 72(9):712-4. PubMed ID: 25252236.
    Abstract:
    Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.
    [Abstract] [Full Text] [Related] [New Search]